Procalcitonin-guided algorithms of antibiotic therapy in the intensive care unit: a systematic review and meta-analysis of randomized controlled trials
- PMID: 20729729
- DOI: 10.1097/CCM.0b013e3181f17bf9
Procalcitonin-guided algorithms of antibiotic therapy in the intensive care unit: a systematic review and meta-analysis of randomized controlled trials
Abstract
Objective: There is increasing interest for strategies that could curtail antibiotic resistance in the critical care setting. We sought to determine the effectiveness and safety of procalcitonin-guided algorithms in the management of septic patients in the intensive care unit.
Data sources: MEDLINE, Scopus, Cochrane Central Register of Controlled Trials (through April 2010), reference lists of retrieved publications, and queries of corresponding authors. No language restrictions were applied.
Study selection: We included only randomized controlled studies reporting on antibiotic use and clinical outcomes of intensive care unit patients managed with a procalcitonin-guided algorithm or according to routine practice.
Data extraction: Data on study characteristics, interventions, and outcomes were retrieved by two independent reviewers. Pooled odds ratios, weighted mean differences, and 95% confidence intervals were calculated by implementing both the Mantel-Haenszel fixed effect model and the DerSimonian-Laird random effects model.
Data synthesis: Seven randomized controlled studies involving 1131 intensive care unit patients (adults = 1010; neonates = 121) were included. In comparison with routine practice, the implementation of procalcitonin-guided algorithms decreased the duration of antibiotic therapy for the first episode of infection by approximately 2 days (weighted mean difference = -2.36 days; 95% confidence interval, -3.11 to -1.61) and the total duration of antibiotic treatment by 4 days (fixed effect model: weighted mean difference: -4.19 days; 95% confidence interval, -4.98 to -3.39). The comparison between the procalcitonin and the routine practice group was not associated with any apparent adverse clinical outcome: 28-day mortality (fixed effect model: odds ratio = 0.93; 95% confidence interval, 0.69 to 1.26), intensive care unit length of stay (fixed effect model: pooled weighted mean difference = -0.49 days, 95% confidence interval, -1.55 to 0.57), and relapsed/persistent infection rate (fixed effect model: odds ratio = 0.97; 95% confidence interval, 0.56 to 1.69).
Conclusions: The implementation of a procalcitonin-based algorithm may reduce antibiotic exposure in critically ill, septic patients without compromising clinical outcomes, but further research is necessary before the wide adoption of this strategy.
Trial registration: ClinicalTrials.gov NCT01085994.
Similar articles
-
Procalcitonin to initiate or discontinue antibiotics in acute respiratory tract infections.Cochrane Database Syst Rev. 2017 Oct 12;10(10):CD007498. doi: 10.1002/14651858.CD007498.pub3. Cochrane Database Syst Rev. 2017. PMID: 29025194 Free PMC article. Review.
-
Procalcitonin testing to guide antibiotic therapy for the treatment of sepsis in intensive care settings and for suspected bacterial infection in emergency department settings: a systematic review and cost-effectiveness analysis.Health Technol Assess. 2015 Nov;19(96):v-xxv, 1-236. doi: 10.3310/hta19960. Health Technol Assess. 2015. PMID: 26569153 Free PMC article. Review.
-
Procalcitonin-guided therapy in intensive care unit patients with severe sepsis and septic shock--a systematic review and meta-analysis.Crit Care. 2013 Dec 11;17(6):R291. doi: 10.1186/cc13157. Crit Care. 2013. PMID: 24330744 Free PMC article. Review.
-
Procalcitonin to initiate or discontinue antibiotics in acute respiratory tract infections.Evid Based Child Health. 2013 Jul;8(4):1297-371. doi: 10.1002/ebch.1927. Evid Based Child Health. 2013. PMID: 23877944 Review.
-
Procalcitonin for reduced antibiotic exposure in the critical care setting: a systematic review and an economic evaluation.Crit Care Med. 2011 Jul;39(7):1792-9. doi: 10.1097/CCM.0b013e31821201a5. Crit Care Med. 2011. PMID: 21358400 Review.
Cited by
-
Evaluation of Serial Procalcitonin Levels for the Optimization of Antibiotic Use in Non-Critically Ill COVID-19 Patients.Pharmaceuticals (Basel). 2024 May 12;17(5):624. doi: 10.3390/ph17050624. Pharmaceuticals (Basel). 2024. PMID: 38794194 Free PMC article.
-
Management of Intra-Abdominal Infections: The Role of Procalcitonin.Antibiotics (Basel). 2023 Sep 4;12(9):1406. doi: 10.3390/antibiotics12091406. Antibiotics (Basel). 2023. PMID: 37760703 Free PMC article. Review.
-
Comprehensive Comparison of the Capacity of Functionalized Sepharose, Magnetic Core, and Polystyrene Nanoparticles to Immuno-Precipitate Procalcitonin from Human Material for the Subsequent Quantification by LC-MS/MS.Int J Mol Sci. 2023 Jun 30;24(13):10963. doi: 10.3390/ijms241310963. Int J Mol Sci. 2023. PMID: 37446139 Free PMC article.
-
MicroRNA Expression Profile in Patients Admitted to ICU as Novel and Reliable Approach for Diagnostic and Therapeutic Purposes.Mol Biotechnol. 2024 Jun;66(6):1357-1375. doi: 10.1007/s12033-023-00767-2. Epub 2023 Jun 14. Mol Biotechnol. 2024. PMID: 37314613 Review.
-
Non-thyroidal illness syndrome and its relationship with mortality risk in critically ill children.Front Pediatr. 2023 Mar 3;11:1142332. doi: 10.3389/fped.2023.1142332. eCollection 2023. Front Pediatr. 2023. PMID: 36937966 Free PMC article.
Publication types
MeSH terms
Substances
Associated data
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous